TI
BIB icon

Trexquant Investment’s ProShares Ultra NASDAQ Biotechnology BIB Stock Holding History

Trexquant Investment’s Portfolio BIB Stock Details BIB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-5,647
Closed -$261K – 1163
2020
Q1 		$261K Buy
+5,647
New +$315K 0.02% 902

Other funds holding BIB

GWM
Geneos Wealth Management Englewood, Colorado $4.31B AUM 18.36% 1-Year Est. Return
CIC
Chase Investment Counsel Charlottesville, Virginia $381M AUM 69.8% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
TFA
Toth Financial Advisory Leesburg, Virginia $1.02B AUM 28.36% 1-Year Est. Return
CIA
Capital Investment Advisors Atlanta, Georgia $6.84B AUM 17.28% 1-Year Est. Return
Bank Julius Baer & Co
Bank Julius Baer & Co Zurich, Switzerland $33.2B AUM 25.01% 1-Year Est. Return
SW
SkyOak Wealth Southfield, Michigan $546M AUM 18.14% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Koshinski Asset Management
Koshinski Asset Management Decatur, Illinois $1.6B AUM 20.7% 1-Year Est. Return
Simplex Trading
Simplex Trading Chicago, Illinois $149B AUM 62.07% 1-Year Est. Return

Trexquant Investment's BIB Position: Q2 2020 in Review

Trexquant Investment sold out of ProShares Ultra NASDAQ Biotechnology (BIB) in Q2 2020, closing a stake of 5,647 shares — an estimated $261K sold.

Trexquant Investment first reported a position in BIB in Q1 2020 and held it in 1 quarter. The position peaked at $261K in Q1 2020. 27 funds tracked by Wall St. Rank hold BIB as of Q2 2020.

  • Trexquant Investment reported no remaining ProShares Ultra NASDAQ Biotechnology position as of Q2 2020 after selling out during the quarter.
  • Trexquant Investment sold 5,647 ProShares Ultra NASDAQ Biotechnology shares in Q2 2020, an estimated $261K.
  • Trexquant Investment first reported a position in ProShares Ultra NASDAQ Biotechnology in Q1 2020 and held it in 1 quarter.
  • Trexquant Investment's ProShares Ultra NASDAQ Biotechnology position peaked at $261K in Q1 2020.
  • 27 funds tracked by Wall St. Rank held ProShares Ultra NASDAQ Biotechnology as of Q2 2020.

Based on Trexquant Investment's 13F filing for Q2 2020, filed 7 Aug 2020.